Abbisko Cayman Limited (HKG:2256)
Hong Kong · Delayed Price · Currency is HKD 10.60
+0.40 (3.92%)
Aug 20, 2026, 4:09 PM HKT
Abbisko Cayman Market Cap
Abbisko Cayman has a market cap or net worth of 7.59 billion as of August 20, 2026. Its market cap has decreased by -33.95% in one year.
Market Cap
7.59B
Enterprise Value
5.60B
Revenue
681.17M
Ranking
n/a
PE Ratio
107.70
Stock Price
10.60
ChartMarket Cap Chart
Since October 15, 2021, Abbisko Cayman's market cap has decreased from 8.71B to 7.59B, a decrease of -12.81%. That is a compound annual growth rate of -2.79%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 20, 2026 | 7.59B | -13.18% |
| Dec 31, 2025 | 8.75B | 204.13% |
| Dec 31, 2024 | 2.88B | 21.63% |
| Dec 29, 2023 | 2.36B | 4.97% |
| Dec 30, 2022 | 2.25B | -64.77% |
| Dec 31, 2021 | 6.39B | -26.60% |
| Oct 15, 2021 | 8.71B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Shaanxi Micot Pharmaceutical Technology | 10.15B |
| TenNor Therapeutics (Suzhou) | 9.31B |
| CARsgen Therapeutics Holdings | 8.86B |
| Everest Medicines | 8.36B |
| Suzhou Ribo Life Science | 8.36B |
| CStone Pharmaceuticals | 8.18B |
| Alphamab Oncology | 7.81B |
| LongBio Pharma (Suzhou) | 7.81B |